[{"id":"13b4bbab-cc06-4064-873f-d9af6714b5de","acronym":"SJATRT","url":"https://clinicaltrials.gov/study/NCT02114229","created_at":"2021-01-18T09:46:59.452Z","updated_at":"2025-02-25T14:56:56.615Z","phase":"Phase 2","brief_title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","source_id_and_acronym":"NCT02114229 - SJATRT","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • topotecan • alisertib (MLN8237) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 05/14/2014","start_date":" 05/14/2014","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-10-31"},{"id":"3f4801d6-52e8-46ea-a4ce-c058e7891e0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02187991","created_at":"2021-01-18T10:12:40.272Z","updated_at":"2025-02-25T14:57:00.891Z","phase":"Phase 2","brief_title":"Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer","source_id_and_acronym":"NCT02187991","lead_sponsor":"US Oncology Research","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 169","initiation":"Initiation: 02/12/2015","start_date":" 02/12/2015","primary_txt":" Primary completion: 04/11/2024","primary_completion_date":" 04/11/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-10-09"},{"id":"66566ad0-5762-43b1-aaba-eb5e68316afa","acronym":"NCI-2019-05913","url":"https://clinicaltrials.gov/study/NCT04085315","created_at":"2021-01-18T19:59:58.628Z","updated_at":"2024-07-02T16:34:36.874Z","phase":"Phase 1","brief_title":"Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer","source_id_and_acronym":"NCT04085315 - NCI-2019-05913","lead_sponsor":"Collin Blakely","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • alisertib (MLN8237)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/12/2019","start_date":" 11/12/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-10"},{"id":"c4a67b85-d57e-45f1-9a88-e437704888be","acronym":"","url":"https://clinicaltrials.gov/study/NCT04479306","created_at":"2021-01-18T21:30:41.583Z","updated_at":"2024-07-02T16:34:59.204Z","phase":"Phase 1","brief_title":"Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04479306","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 21 deletion","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 21 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • sapanisertib (CB-228) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 07/27/2023","primary_completion_date":" 07/27/2023","study_txt":" Completion: 07/27/2023","study_completion_date":" 07/27/2023","last_update_posted":"2024-06-04"},{"id":"d0d47c61-61e0-4557-9a9c-103d7e9e6b56","acronym":"","url":"https://clinicaltrials.gov/study/NCT01695941","created_at":"2021-01-29T07:03:45.178Z","updated_at":"2024-07-02T16:35:15.783Z","phase":"Phase 1","brief_title":"Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01695941","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • alisertib (MLN8237) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/31/2012","start_date":" 08/31/2012","primary_txt":" Primary completion: 05/29/2018","primary_completion_date":" 05/29/2018","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-03-07"},{"id":"61980c8d-d0ee-473a-8ed7-51d563eba43c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02860000","created_at":"2021-01-18T14:02:22.687Z","updated_at":"2024-07-02T16:35:22.988Z","phase":"Phase 2","brief_title":"Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer","source_id_and_acronym":"NCT02860000","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 amplification • HER-2 negative • HER-2 expression • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 amplification • HER-2 negative • HER-2 expression • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • alisertib (MLN8237)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/06/2017","start_date":" 07/06/2017","primary_txt":" Primary completion: 01/10/2022","primary_completion_date":" 01/10/2022","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-01-18"},{"id":"4af2b883-4b5c-4b1a-b8a8-6f3373185c01","acronym":"","url":"https://clinicaltrials.gov/study/NCT02719691","created_at":"2021-01-18T13:18:17.871Z","updated_at":"2024-07-02T16:36:06.763Z","phase":"Phase 1","brief_title":"Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT02719691","lead_sponsor":"University of Colorado, Denver","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 05/13/2016","start_date":" 05/13/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 03/18/2020","study_completion_date":" 03/18/2020","last_update_posted":"2022-07-25"},{"id":"5827b671-dca3-46e1-b8fa-8ec420f73112","acronym":"","url":"https://clinicaltrials.gov/study/NCT00853307","created_at":"2021-01-18T03:14:54.704Z","updated_at":"2024-07-02T16:36:13.437Z","phase":"Phase 2","brief_title":"MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma","source_id_and_acronym":"NCT00853307","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 03/23/2009","start_date":" 03/23/2009","primary_txt":" Primary completion: 11/23/2009","primary_completion_date":" 11/23/2009","study_txt":" Completion: 01/27/2011","study_completion_date":" 01/27/2011","last_update_posted":"2022-04-08"},{"id":"47bf8c34-12d0-4fbd-900e-a934d4279c7a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01154816","created_at":"2021-01-18T04:35:50.917Z","updated_at":"2024-07-02T16:36:45.053Z","phase":"Phase 2","brief_title":"Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia","source_id_and_acronym":"NCT01154816","lead_sponsor":"Children's Oncology Group","biomarkers":" SMARCD3","pipe":"","alterations":" ","tags":["SMARCD3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 02/01/2011","start_date":" 02/01/2011","primary_txt":" Primary completion: 12/31/2015","primary_completion_date":" 12/31/2015","study_txt":" Completion: 06/30/2019","study_completion_date":" 06/30/2019","last_update_posted":"2020-05-13"},{"id":"bb4a6aa4-08e9-4d44-bc20-09c982a16bd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02327169","created_at":"2021-01-18T11:02:33.167Z","updated_at":"2024-07-02T16:36:49.576Z","phase":"Phase 1b","brief_title":"A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies","source_id_and_acronym":"NCT02327169","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF mutation • KRAS exon 2 mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • paclitaxel • irinotecan • sapanisertib (CB-228) • Ojemda (tovorafenib) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 01/14/2015","start_date":" 01/14/2015","primary_txt":" Primary completion: 07/02/2018","primary_completion_date":" 07/02/2018","study_txt":" Completion: 07/02/2018","study_completion_date":" 07/02/2018","last_update_posted":"2020-02-25"},{"id":"ef3dd037-0458-48e4-a78e-804144c632c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01601535","created_at":"2021-01-18T06:50:55.923Z","updated_at":"2024-07-02T16:36:57.512Z","phase":"Phase 1/2","brief_title":"Study of MLN8237 in Combination With Irinotecan and Temozolomide","source_id_and_acronym":"NCT01601535","lead_sponsor":"New Approaches to Neuroblastoma Therapy Consortium","biomarkers":" UGT1A1 • AURKA","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • AURKA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 05/01/2012","start_date":" 05/01/2012","primary_txt":" Primary completion: 07/25/2018","primary_completion_date":" 07/25/2018","study_txt":" Completion: 07/25/2018","study_completion_date":" 07/25/2018","last_update_posted":"2019-07-31"},{"id":"8defb032-2019-4105-9185-f94f7249e01c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00697346","created_at":"2021-01-18T02:36:25.810Z","updated_at":"2024-07-02T16:36:59.184Z","phase":"Phase 1","brief_title":"Study of MLN8237 in Participants With Advanced Hematological Malignancies","source_id_and_acronym":"NCT00697346","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" UGT1A1 • AURKA","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • AURKA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 07/11/2008","start_date":" 07/11/2008","primary_txt":" Primary completion: 10/01/2016","primary_completion_date":" 10/01/2016","study_txt":" Completion: 10/19/2016","study_completion_date":" 10/19/2016","last_update_posted":"2019-05-31"},{"id":"efdca036-7d79-49e0-a135-b8831a3daa49","acronym":"","url":"https://clinicaltrials.gov/study/NCT00500903","created_at":"2021-01-18T01:47:45.504Z","updated_at":"2024-07-02T16:37:01.880Z","phase":"Phase 1","brief_title":"A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT00500903","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 87","initiation":"Initiation: 05/15/2007","start_date":" 05/15/2007","primary_txt":" Primary completion: 08/01/2010","primary_completion_date":" 08/01/2010","study_txt":" Completion: 02/23/2011","study_completion_date":" 02/23/2011","last_update_posted":"2019-03-14"},{"id":"396316cf-b663-4dd0-81ce-d6e47945f737","acronym":"","url":"https://clinicaltrials.gov/study/NCT01897012","created_at":"2021-01-18T08:30:51.764Z","updated_at":"2024-07-02T16:37:03.460Z","phase":"Phase 1","brief_title":"Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas","source_id_and_acronym":"NCT01897012","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" MYC positive","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 07/17/2013","start_date":" 07/17/2013","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 11/30/2018","study_completion_date":" 11/30/2018","last_update_posted":"2019-01-28"},{"id":"de96ee65-4bd6-4e75-99e2-105c6c3ed1cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02219789","created_at":"2021-01-18T10:24:13.359Z","updated_at":"2024-07-02T16:37:06.442Z","phase":"Phase 1","brief_title":"Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02219789","lead_sponsor":"Mayo Clinic","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 12/05/2014","start_date":" 12/05/2014","primary_txt":" Primary completion: 03/28/2016","primary_completion_date":" 03/28/2016","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2018-10-03"},{"id":"607bdc5d-4425-4b6b-a0bd-18cedbef88b7","acronym":"AD3LE","url":"https://clinicaltrials.gov/study/NCT02780011","created_at":"2021-01-18T13:38:09.817Z","updated_at":"2025-02-25T14:50:09.022Z","phase":"Phase 1","brief_title":"Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies","source_id_and_acronym":"NCT02780011 - AD3LE","lead_sponsor":"Eric Bernicker, MD","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • alisertib (MLN8237)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2018-07-27"},{"id":"33e08fb0-d8a7-404a-aa16-ca024c269557","acronym":"","url":"https://clinicaltrials.gov/study/NCT01091428","created_at":"2021-01-18T04:18:47.293Z","updated_at":"2024-07-02T16:37:10.329Z","phase":"Phase 2","brief_title":"Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer","source_id_and_acronym":"NCT01091428","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 191","initiation":"Initiation: 04/16/2010","start_date":" 04/16/2010","primary_txt":" Primary completion: 08/12/2014","primary_completion_date":" 08/12/2014","study_txt":" Completion: 07/19/2017","study_completion_date":" 07/19/2017","last_update_posted":"2018-06-04"},{"id":"70fe7718-642c-41e1-b50c-226eb8ac890c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01799278","created_at":"2021-01-18T07:57:50.545Z","updated_at":"2025-02-25T14:56:36.212Z","phase":"Phase 2","brief_title":"A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer","source_id_and_acronym":"NCT01799278","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" SYP • CHGA","pipe":"","alterations":" ","tags":["SYP • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 08/01/2017","study_completion_date":" 08/01/2017","last_update_posted":"2018-01-23"},{"id":"3b0a3f00-fc96-4fd8-b90d-f41daa3423e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01779843","created_at":"2021-01-18T07:50:50.749Z","updated_at":"2024-07-02T16:37:25.597Z","phase":"Phase 1","brief_title":"Alisertib for Acute Myeloid Leukemia","source_id_and_acronym":"NCT01779843","lead_sponsor":"Massachusetts General Hospital","biomarkers":" AURKA","pipe":"","alterations":" ","tags":["AURKA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2017-02-17"},{"id":"ab5bcdd3-b10a-4a4d-ad92-e9366790f658","acronym":"","url":"https://clinicaltrials.gov/study/NCT01045421","created_at":"2023-03-23T22:25:00.603Z","updated_at":"2024-07-02T16:37:29.781Z","phase":"Phase 1/2","brief_title":"Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies","source_id_and_acronym":"NCT01045421","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 273","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2016-08-15"}]